
“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.